<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: This phase II investigated efficacy and tolerability of <z:chebi fb="0" ids="49668">gefitinib</z:chebi> in combination with paclitaxel (P) and <z:chebi fb="2" ids="31355">carboplatin</z:chebi> (C) for second-line treatment of patients (pts) with ovarian, tubal or peritoneal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Women (&gt;18 years) with <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-resistant/refractory (relapsed&lt;6 months), or <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-sensitive (relapsed &gt;6 months) disease after first-line <z:chebi fb="240" ids="33364,33400">platinum</z:chebi>-based and P chemotherapy </plain></SENT>
<SENT sid="2" pm="."><plain>Pts received 6-8 cycles of <z:chebi fb="0" ids="49668">gefitinib</z:chebi> (500 mg/day), P (175 mg/m(2) 3 h infusion) and C (AUC 5) every 3 weeks, followed by <z:chebi fb="0" ids="49668">gefitinib</z:chebi> alone </plain></SENT>
<SENT sid="3" pm="."><plain>The primary endpoint was objective response rate (ORR) (RECIST or Rustin criteria) </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Sixty-eight patients (26 resistant/refractory and 42 sensitive) were enrolled (median age: 57 years) </plain></SENT>
<SENT sid="5" pm="."><plain>ORR and disease control rates were 19.2% and 69.2% for resistant/refractory, and 61.9% and 81.0%, for sensitive disease </plain></SENT>
<SENT sid="6" pm="."><plain>Median time to progression and overall median survivals were 6.1 and 16.9 months for resistant/refractory and 9.2 and 25.7 months for sensitive disease </plain></SENT>
<SENT sid="7" pm="."><plain>Grade 3/4 toxicities (in &gt; or = 10% patients) were <z:hpo ids='HP_0001875'>neutropenia</z:hpo> (59%), <z:hpo ids='HP_0002014'>diarrhea</z:hpo> (25%), <z:hpo ids='HP_0001882'>leukopenia</z:hpo> (22%), <z:hpo ids='HP_0001903'>anemia</z:hpo> (13%), and <z:hpo ids='HP_0001061'>acne</z:hpo> (13%) </plain></SENT>
<SENT sid="8" pm="."><plain>Two secondary <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and one secondary <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> occurred during treatment, and one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> 34 months after treatment discontinuation </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: <z:chebi fb="0" ids="49668">Gefitinib</z:chebi>, administered in combination with paclitaxel and <z:chebi fb="2" ids="31355">carboplatin</z:chebi>, provides a good clinical response but associated with an increased risk of <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> </plain></SENT>
</text></document>